
IMIC Medical Research Center Adds New Agents to ACTIV-2 Clinical Trial in Miami Dade to Investigate Early COVID-19 Treatments
WHAT: The ACTIV-2 clinical trial, which is investigating treatments for early COVID-19, announces the addition of new agents to the study. Developed by Brii Biosciences, BRII-196 and BRII-198 are monoclonal antibodies that each target a different part of SARS-CoV-2, the…